» Articles » PMID: 17308309

Abeta Oligomers Induce Neuronal Oxidative Stress Through an N-methyl-D-aspartate Receptor-dependent Mechanism That is Blocked by the Alzheimer Drug Memantine

Overview
Journal J Biol Chem
Specialty Biochemistry
Date 2007 Feb 20
PMID 17308309
Citations 426
Authors
Affiliations
Soon will be listed here.
Abstract

Oxidative stress is a major aspect of Alzheimer disease (AD) pathology. We have investigated the relationship between oxidative stress and neuronal binding of Abeta oligomers (also known as ADDLs). ADDLs are known to accumulate in brain tissue of AD patients and are considered centrally related to pathogenesis. Using hippocampal neuronal cultures, we found that ADDLs stimulated excessive formation of reactive oxygen species (ROS) through a mechanism requiring N-methyl-d-aspartate receptor (NMDA-R) activation. ADDL binding to neurons was reduced and ROS formation was completely blocked by an antibody to the extracellular domain of the NR1 subunit of NMDA-Rs. In harmony with a steric inhibition of ADDL binding by NR1 antibodies, ADDLs that were bound to detergent-extracted synaptosomal membranes co-immunoprecipitated with NMDA-R subunits. The NR1 antibody did not affect ROS formation induced by NMDA, showing that NMDA-Rs themselves remained functional. Memantine, an open channel NMDA-R antagonist prescribed as a memory-preserving drug for AD patients, completely protected against ADDL-induced ROS formation, as did other NMDA-R antagonists. Memantine and the anti-NR1 antibody also attenuated a rapid ADDL-induced increase in intraneuronal calcium, which was essential for stimulated ROS formation. These results show that ADDLs bind to or in close proximity to NMDA-Rs, triggering neuronal damage through NMDA-R-dependent calcium flux. This response provides a pathologically specific mechanism for the therapeutic action of memantine, indicates a role for ROS dysregulation in ADDL-induced cognitive impairment, and supports the unifying hypothesis that ADDLs play a central role in AD pathogenesis.

Citing Articles

Type 3 diabetes and metabolic reprogramming of brain neurons: causes and therapeutic strategies.

Meng X, Zhang H, Zhao Z, Li S, Zhang X, Guo R Mol Med. 2025; 31(1):61.

PMID: 39966707 PMC: 11834690. DOI: 10.1186/s10020-025-01101-z.


AMPA receptor diffusional trapping machinery as an early therapeutic target in neurodegenerative and neuropsychiatric disorders.

Choquet D, Opazo P, Zhang H Transl Neurodegener. 2025; 14(1):8.

PMID: 39934896 PMC: 11817889. DOI: 10.1186/s40035-025-00470-z.


Exome sequencing reveals a rare damaging variant in GRIN2C in familial late-onset Alzheimer's disease.

Rubino E, Italia M, Giorgio E, Boschi S, Dimartino P, Pippucci T Alzheimers Res Ther. 2025; 17(1):21.

PMID: 39810256 PMC: 11730494. DOI: 10.1186/s13195-024-01661-y.


The Role of Oligodendrocyte Lineage Cells in the Pathogenesis of Alzheimer's Disease.

Liu X, Lv Z, Huang Q, Lei Y, Liu H, Xu P Neurochem Res. 2025; 50(1):72.

PMID: 39751972 DOI: 10.1007/s11064-024-04325-3.


Memantine/Rosuvastatin Therapy Abrogates Cognitive and Hippocampal Injury in an Experimental Model of Alzheimer's Disease in Rats: Role of TGF-β1/Smad Signaling Pathway and Amyloid-β Clearance.

Zidan E, El-Mezayen N, Elrewini S, Afify E, Ali M J Neuroimmune Pharmacol. 2024; 20(1):4.

PMID: 39708240 PMC: 11663181. DOI: 10.1007/s11481-024-10159-1.